Incidence and characterization of acute HIV-1 infection in a high-risk Thai population

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 2, 2008, Pages 151-155

  Ananworanich, Jintanat ^a,b,e   Phanuphak, Nittaya ^c   De Souza, Mark ^a   Paris, Robert ^a   Arroyo, Miguel ^a   Trichavaroj, Rapee ^a   Sirivichayakul, Sunee ^c,d   Shikuma, Cecilia ^b   Phanuphak, Praphan ^c   Kim, Jerome H ^a  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b UNIVERSITY OF HAWAII   (United States)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e South East Asia Research Collaboration with Hawaii ^*  (Thailand)

Author keywords

Acute HIV infection; Fiebig; Pooled nucleic acid testing; Sequential EIA; Thailand

Indexed keywords

VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; THAILAND; VIRUS LOAD; VIRUS STRAIN; ANTIVIRAL RESISTANCE; BLOOD; CLASSIFICATION; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; SEXUAL BEHAVIOR; VIROLOGY;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RNA, VIRAL; SEXUAL BEHAVIOR; THAILAND; VIRAL LOAD;

EID: 55249112694     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318183a96d     Document Type: Article

References (33)

1. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol. 2006;7:235-239.
2. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749-759.
3. Celum CL, Buchbinder SP, Donnell D, et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis. 2001;183:23-35.
4. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403-1409.
5. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005;352: 1873-1883.
6. Pilcher CD, MePherson JT, Leone PA, et al. Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA. 2002;288:216-221.
7. Preiser W. HIV Testing. In: Hoffmann C, Rockstroh J, eds. HIV Medicine. Paris, France: Flying Publisher; 2005.
8. UNAIDS. 2006 Report on the Global AIDS Epidemic. Available at: http:// www.unaids.org/eri/HIV-data/2006GlobalReport/default.asp. Accessed February 1, 2007.
9. Chen XS, Yin YP, Tucker JD, et al. Detection of acute and established HIV infections in sexually transmitted disease clinics in Guangxi, China: implications for screening and prevention of HIV infection. J Infect Dis. 2007;196:1654-1661.
10. Khongphatthanayothin M, Tantipaibulvut S, Nookai S, et al. Demographic predictors of a positive HIV test result among clients attending a large metropolitan voluntary counselling and testing centre in Thailand. HIV Med. 2006;7:281-284.
11. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-1879.
12. Kijak GH, Tovanabutra S, Sanders-Buell E, et al. Distinguishing molecular forms of HIV-1 in Asia with a high-throughput, fluorescent genotyping assay, MHAbce v.2. Virology. 2007;358:178-191.
13. Brookmeyer R. Analysis of multistage pooling studies of biological specimens for estimating disease incidence and prevalence. Biometrics. 1999;55:608-612.
14. van Griensven F, Thanprasertsuk S, Jommaroeng R, et al. Evidence of a previously undocumented epidemic of HIV infection among men who have sex with men in Bangkok, Thailand. AIDS. 2005;19:521-526.
15. Mansergh G, Naorat S, Jommaroeng R, et al. Inconsistent condom use with steady and casual partners and associated factors among sexuallyactive men who have sex with men in Bangkok, Thailand. AIDS Behav. 2006;10:743-751.
16. Beyrer C, Sripaipan T, Tovanabutra S, et al. High HIV, hepatitis C and sexual risks among drug-using men who have sex with men in northern Thailand. AIDS. 2005;19:1535-1540.
17. McCutchan FE. Global epidemiology of HIV. J Med Virol. 2006;78 (Suppl 1):S7-S12.
18. Brown BK, Darden JM, Tovanabutra S, et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRFOl-AE, and CRF02-AG, for the development and assessment of candidate vaccines. J Virol. 2005;79: 6089-6101.
19. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-I infection. J Infect Dis. 2007;195: 951-959.
20. Pillay D, Fisher M. Primary HIV Infection, phylogenetics, and antiretroviral prevention. J Infect Dis. 2007;195:924-926.
21. Arroyo MA, Saferen WB, Serwadda D, et al. Higher HIV-1 incidence and genetic complexity along main roads in Rakai District, Uganda. J Acquir Immune Defic Syndr. 2006;43:440-445.
22. Watanaveeradej V, Benenson MW, Souza MD, et al. Molecular epidemiology of HIV Type 1 in preparation for a Phase III prime-boost vaccine trial in Thailand and a new approach to HIV Type 1 genotyping. AIDS Res Hum Retroviruses. 2006;22:801-807.
23. Xiridou M, van Griensven F, Tappero JW, et al. The spread of HIV-1 subtypes B and CRFO1-AE among injecting drug users in Bangkok, Thailand. J Acquir Immune Defic Syndr. 2007;45:468-475.
24. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007;15:119-125.
25. Chaix ML, Descamps D, Harzic M, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS. 2003;17:2635-2643.
26. Ross L, Lim ML, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIVinfected individuals from 40 United States cities. HIV Clin Trials. 2007;8: 1-8.
27. Mini stry of Public Health. Thailand. National Guidelines for the Clinical Management of HIV Infection in Children and Adult. The Bureau of AIDS, TB and STI, Ministry of Public Health. Bangkok, Thailand; 2007.
28. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-843.
29. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis. 2006;194:725-733.
30. Goujard C, Marcellin F, Hendel-Chavez H, et al. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. AIDS Res Hum Retroviruses. 2007;23:1105-1113.
31. Lafeuillade A, Poggi C, Hittinger G, et al. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J Infect Dis. 2003;188:1426-1432.
32. Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis. 2007;195: 1762-1764.
33. Margolis DM, Archin NM. Eliminating persistent HIV infection: getting to the end of the rainbow. J Infect Dis. 2007;195:1734-1736.